- Home
- DGNX vs XNCR Comparison
DGNX vs XNCR Comparison
Compare DGNX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- XNCR
- Stock Information
- Founded
- DGNX 2018
- XNCR 1997
- Country
- DGNX Hong Kong
- XNCR United States
- Employees
- DGNX N/A
- XNCR N/A
- Industry
- DGNX
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- DGNX
- XNCR Health Care
- Exchange
- DGNX NYSE
- XNCR Nasdaq
- Market Cap
- DGNX 1.2B
- XNCR 1.1B
- IPO Year
- DGNX 2025
- XNCR 2013
- Fundamental
- Price
- DGNX $54.13
- XNCR $13.87
- Analyst Decision
- DGNX
- XNCR Strong Buy
- Analyst Count
- DGNX 0
- XNCR 8
- Target Price
- DGNX N/A
- XNCR $34.63
- AVG Volume (30 Days)
- DGNX 139.2K
- XNCR 552.5K
- Earning Date
- DGNX 01-01-0001
- XNCR 02-27-2025
- Dividend Yield
- DGNX N/A
- XNCR N/A
- EPS Growth
- DGNX N/A
- XNCR N/A
- EPS
- DGNX N/A
- XNCR N/A
- Revenue
- DGNX $1,177,066.00
- XNCR $110,493,000.00
- Revenue This Year
- DGNX N/A
- XNCR $0.74
- Revenue Next Year
- DGNX N/A
- XNCR $37.36
- P/E Ratio
- DGNX N/A
- XNCR N/A
- Revenue Growth
- DGNX N/A
- XNCR N/A
- 52 Week Low
- DGNX $3.60
- XNCR $13.42
- 52 Week High
- DGNX $82.51
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- XNCR 24.03
- Support Level
- DGNX N/A
- XNCR $13.42
- Resistance Level
- DGNX N/A
- XNCR $14.60
- Average True Range (ATR)
- DGNX 0.00
- XNCR 0.74
- MACD
- DGNX 0.00
- XNCR 0.04
- Stochastic Oscillator
- DGNX 0.00
- XNCR 13.78
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.